Five Prime Therapeutics Inc. [NASDAQ: FPRX] price surged by 11.10 percent to reach at $2.38. The company report on February 5, 2021 that Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer, are scheduled to participate in a fireside chat at the virtual Guggenheim Healthcare Talks: Oncology Day on Friday, February 12, 2021 at 1:00 p.m. ET/10:00 a.m. PT.
Live audio webcast of the fireside chat will be accessible and available for replay from the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
A sum of 1199873 shares traded at recent session while its average daily volume was at 905.21K shares. Five Prime Therapeutics Inc. shares reached a high of $23.87 and dropped to a low of $21.20 until finishing in the latest session at $23.82.
The one-year FPRX stock forecast points to a potential upside of 12.72. The average equity rating for FPRX stock is currently 1.60, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Five Prime Therapeutics Inc. [FPRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FPRX shares is $27.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FPRX stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Five Prime Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 11, 2020. While these analysts kept the previous recommendation, ROTH Capital dropped their target price from $9 to $30. The new note on the price target was released on November 11, 2020, representing the official price target for Five Prime Therapeutics Inc. stock. Previously, the target price had yet another raise to $14, while JP Morgan analysts kept a Neutral rating on FPRX stock.
The Average True Range (ATR) for Five Prime Therapeutics Inc. is set at 1.50, with the Price to Sales ratio for FPRX stock in the period of the last 12 months amounting to 55.04. The Price to Book ratio for the last quarter was 8.89, with the Price to Cash per share for the same quarter was set at 2.82.
FPRX Stock Performance Analysis:
Five Prime Therapeutics Inc. [FPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.58. With this latest performance, FPRX shares gained by 60.73% in over the last four-week period, additionally plugging by 398.33% over the last 6 months – not to mention a rise of 344.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FPRX stock in for the last two-week period is set at 74.71, with the RSI for the last a single of trading hit 81.84, and the three-weeks RSI is set at 69.84 for Five Prime Therapeutics Inc. [FPRX]. The present Moving Average for the last 50 days of trading for this stock 17.80, while it was recorded at 21.14 for the last single week of trading, and 9.50 for the last 200 days.
Insight into Five Prime Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Five Prime Therapeutics Inc. [FPRX] shares currently have an operating margin of -909.80. Five Prime Therapeutics Inc.’s Net Margin is presently recorded at -922.43.
Return on Total Capital for FPRX is now -58.18, given the latest momentum, and Return on Invested Capital for the company is -59.51. Return on Equity for this stock declined to -66.02, with Return on Assets sitting at -50.29. When it comes to the capital structure of this company, Five Prime Therapeutics Inc. [FPRX] has a Total Debt to Total Equity ratio set at 32.97. Additionally, FPRX Total Debt to Total Capital is recorded at 24.80, with Total Debt to Total Assets ending up at 22.13. Long-Term Debt to Equity for the company is recorded at 30.26, with the Long-Term Debt to Total Capital now at 22.76.
Reflecting on the efficiency of the workforce at the company, Five Prime Therapeutics Inc. [FPRX] managed to generate an average of -$1,577,034 per employee. Receivables Turnover for the company is 3.24 with a Total Asset Turnover recorded at a value of 0.05.Five Prime Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.30 and a Current Ratio set at 5.30.
FPRX Stock EPS
With the latest financial reports released by the company, Five Prime Therapeutics Inc. posted -0.89/share EPS, while the average EPS was predicted by analysts to be reported at -0.96/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FPRX.
Five Prime Therapeutics Inc. [FPRX] Insider Position Details
There are presently around $929 million, or 82.50% of FPRX stock, in the hands of institutional investors. The top three institutional holders of FPRX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 4,285,161, which is approximately New of the company’s market cap and around 0.80% of the total institutional ownership; BLACKROCK INC., holding 2,959,031 shares of the stock with an approximate value of $70.48 million in FPRX stocks shares; and RTW INVESTMENTS, LP, currently with $59.93 million in FPRX stock with ownership of nearly New of the company’s market capitalization.
Positions in Five Prime Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 91 institutional holders increased their position in Five Prime Therapeutics Inc. [NASDAQ:FPRX] by around 23,902,107 shares. Additionally, 46 investors decreased positions by around 11,136,256 shares, while 7 investors held positions by with 3,967,944 shares. The mentioned changes placed institutional holdings at 39,006,307 shares, according to the latest SEC report filing. FPRX stock had 51 new institutional investments in for a total of 16,380,865 shares, while 21 institutional investors sold positions of 2,038,154 shares during the same period.